BEIJING, June 27 (Reuters): China's Clover Biopharmaceuticals said on Monday a booster shot of its Covid-19 vaccine candidate significantly increased antibody response against the Omicron coronavirus variant from levels seen after two primary shots.
A third dose of its vaccine candidate SCB-2019 resulted in a 19-fold increase in neutralising antibody levels against the Omicron BA.2 subvariant from pre-booster levels, Clover said in a filing to the Hong Kong stock exchange.
Already a subscriber? Log in
Play, subscribe and stand a chance to win prizes worth over RM39,000! T&C applies.
Cancel anytime. Ad-free. Unlimited access with perks.
